OBI Pharma Inc (台灣浩鼎) yesterday downplayed concerns about data on the clinical trials of its new breast cancer drug, OBI-822, as its shares fell by the maximum daily limit for the second consecutive session this week to NT$481.5.
The company, which has been embroiled in an insider trading scandal over the past few months, held a news conference in Taipei following a presentation on the second and third-phase clinical trials of OBI-822 at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
OBI Pharma said that a significant improvement in progression-free survival (PFS) was seen in about 50 percent of the patients who demonstrated an immune system response to the vaccine, compared with those who received a placebo.
PFS among the subset of patients who developed an immune system response improved to 49 weeks compared with 40 weeks in the placebo group, suggesting a positive effect, the company said.
However, analysts held a reserved outlook on the outcome of the clinical trial after the company briefed local investors on its ASCO presentation in Taipei on Sunday, while declining to comment on regulatory approval progress and commercialization.
For patients who did not develop an immune response, PFS decreased to 24 weeks compared with 40 weeks for patients taking placebo, indicating a potential negative effect on some patients, Yuanta Securities Investment Consulting Co (元大投顧) analyst Peggy Lee (李珮菁) said in a note published on Monday.
She added that the eight-week gain in PFS among patients who have developed a response was not outstanding.
“In our view, the negative effect on patients who did not develop an immune response was unexpectedly negative,” she said.
OBI Pharma rejected the reports as misinformed in a filing with the Taiwan Stock Exchange on Monday evening.
The company said that all patients who received the full regimen of nine injections saw PFS improvements of varying degrees depending on the level of immune system response triggered by the drug.
“The claims of negative effects are baseless, with patients reporting no adverse reactions apart from redness and slight inflammation at the injection site,” the company said in the filing.
The company was also especially strident in correcting analysts’ view that there was no significant difference in globo H expression between patients categorized as responders, non-responders and the control group.
“Our data show the exact opposite,” the company said.
OBI-822 is designed to target globo H and trigger the immune system to respond with cancer-destroying T cells, the company said.
“Although the study shows that there is no significant link between globo H, OBI-822 is effective in encouraging the immune system to produce the desired cancer-fighting antibodies even among patients with with low globo H presence. Therefore, the drug is effective,” the company said, adding that the degree of improvement is more pronounced among patients with higher antibody production.
The company also said that analysts had taken the PFS results out of context, as they had compared OBI-822 with seemingly superior clinical trial results of Ibrance, a rival treatment that has severe side effects, including heightened risk of infections and lowered white blood cell count.
Separately, the company yesterday announced that sales last month came to NT$92.38 million (US$2.86 million), its first entry this year. The money is from a licensing transfer fee for Dificid, a clostridium difficile-associated diarrhea drug the company developed that was approved by the US FDA in 2011.
Taiwan’s technology protection rules prohibits Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) from producing 2-nanometer chips abroad, so the company must keep its most cutting-edge technology at home, Minister of Economic Affairs J.W. Kuo (郭智輝) said yesterday. Kuo made the remarks in response to concerns that TSMC might be forced to produce advanced 2-nanometer chips at its fabs in Arizona ahead of schedule after former US president Donald Trump was re-elected as the next US president on Tuesday. “Since Taiwan has related regulations to protect its own technologies, TSMC cannot produce 2-nanometer chips overseas currently,” Kuo said at a meeting of the legislature’s
GEOPOLITICAL ISSUES? The economics ministry said that political factors should not affect supply chains linking global satellite firms and Taiwanese manufacturers Elon Musk’s Space Exploration Technologies Corp (SpaceX) asked Taiwanese suppliers to transfer manufacturing out of Taiwan, leading to some relocating portions of their supply chain, according to sources employed by and close to the equipment makers and corporate documents. A source at a company that is one of the numerous subcontractors that provide components for SpaceX’s Starlink satellite Internet products said that SpaceX asked their manufacturers to produce outside of Taiwan because of geopolitical risks, pushing at least one to move production to Vietnam. A second source who collaborates with Taiwanese satellite component makers in the nation said that suppliers were directly
Top Taiwanese officials yesterday moved to ease concern about the potential fallout of Donald Trump’s return to the White House, making a case that the technology restrictions promised by the former US president against China would outweigh the risks to the island. The prospect of Trump’s victory in this week’s election is a worry for Taipei given the Republican nominee in the past cast doubt over the US commitment to defend it from Beijing. But other policies championed by Trump toward China hold some appeal for Taiwan. National Development Council Minister Paul Liu (劉鏡清) described the proposed technology curbs as potentially having
EXPORT CONTROLS: US lawmakers have grown more concerned that the US Department of Commerce might not be aggressively enforcing its chip restrictions The US on Friday said it imposed a US$500,000 penalty on New York-based GlobalFoundries Inc, the world’s third-largest contract chipmaker, for shipping chips without authorization to an affiliate of blacklisted Chinese chipmaker Semiconductor Manufacturing International Corp (SMIC, 中芯). The US Department of Commerce in a statement said GlobalFoundries sent 74 shipments worth US$17.1 million to SJ Semiconductor Corp (盛合晶微半導體), an affiliate of SMIC, without seeking a license. Both SMIC and SJ Semiconductor were added to the department’s trade restriction Entity List in 2020 over SMIC’s alleged ties to the Chinese military-industrial complex. SMIC has denied wrongdoing. Exports to firms on the list